Document is current
Any future updates will be listed below
-
Authors
Shah, Aadit P. https://orcid.org/0000-0001-8672-6643
Majeti, Kiran R.
Ekman, Freja K.
Selvaraj, Sridhar
Sharma, Devesh
Sinha, Roshani
Soupene, Eric
Chati, Prathamesh
Luna, Sofia E. https://orcid.org/0000-0002-9173-9518
Charlesworth, Carsten T.
McCreary, Travis
Lesch, Benjamin J.
Tran, Tammy
Chu, Simon N. https://orcid.org/0000-0003-3863-1548
Porteus, Matthew H. https://orcid.org/0000-0002-3850-4648
Kyle Cromer, M. https://orcid.org/0000-0002-8198-5010
-
Funding
Funding for this research was provided by:
UC | UC San Francisco | School of Pharmacy, University of California, San Francisco (Mary Anne Koda-Kimble Seed Award for Innovation)
UC | UC San Francisco | UCSF Foundation (Program for Breakthrough Biomedical Research: New Frontier Research Award)
Stanford University (Knight-Hennessy Scholarship)
Stanford University (Medical Scholars Research Program)
Stanford University (Medical Scientist Training Program)
Paul and Daisy Soros Fellowships for New Americans
Hertz Foundation (Fellowship)
American Society of Hematology (Minority Medical Student Award Program)
California Institute for Regenerative Medicine (Bridges Program)
California Institute for Regenerative Medicine (Bridges Program)
National Science Foundation (Graduate Research Fellowship Program)
U.S. Department of Health & Human Services | National Institutes of Health (T32 Research Training in Transplant Surgery Fellowship (1T32AI125222-01))
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 10 January 2025
First Online: 29 January 2025
Competing interests
: M.H.P. is a member of the scientific advisory board of Allogene Therapeutics. M.H.P. has equity in CRISPR Tx and Kamau Tx. C.T.C., M.H.P., and M.K.C. have filed provisional patent no. PCT/US2023/076969, which includes all synEPOR designs, genomic integration strategies, and the application of EPO-independent erythropoiesis. The remaining authors declare no competing interests.
